Quest for the right Drug
ציטוסאר 1 ג' CYTOSAR 1 G. (CYTARABINE)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
תוך-ורידי : I.V
צורת מינון:
אבקה להכנת תמיסה לזריקה : POWDER FOR SOLUTION FOR INJECTION
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Pharmaceutical particulars : מידע רוקחי
6. PHARMACEUTICAL PARTICULARS 6.1 List of excipients Hydrochloric Acid conc. 2020-0061980 Page 8 of 10 Sodium Hydroxide (disks) Nitrogen Water for injections 6.2 Incompatibilities In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products except those mentioned in sections 4.2 and 6.3 . 6.3 Shelf-life The expiry date of the product is indicated on the packaging materials Stability in Infusion Solutions Chemical and physical stability studies of cytarabine have demonstrated that cytarabine is stable for seven days at room temperature when admixed at 0.5 mg/ml in glass IV bottles and plastic IV bags with: water for injection; 5% Dextrose injection; and 0.9% Sodium Chloride injection solutions. Also when similarly admixed at 8-32 mg/ml in glass IV bottles and plastic IV bags, cytarabine is stable for seven days at room temperature, -20 degrees C, and 4 degrees C in 5% Dextrose Injection; 5% Dextrose in 0.2% Sodium Chloride Injection; and, in 0.9% Sodium Chloride Injection Solutions. Cytarabine is stable at room temperature at a concentration of 2 mg/ml in the presence of KCl equivalent to 50 meg/500 ml in Dextrose 5% in water and 0.9% Sodium Chloride for up to eight days. Cytarabine is also stable at room temperature and at refrigerated temperature (8 degrees C) at a concentration of 0.2-1.0 mg/ml in the presence of Sodium Bicarbonate equivalent to 50 meq/L in Dextrose 5% in Water or Dextrose 5% in 0.2% Sodium Chloride for seven days in Travenol glass bottles or Viaflex bags. Cytarabine injection, and the infused solutions prepared therefrom, contain(s) no antimicrobial agents. Therefore, it is recommended that further dilution be effected immediately prior to use and infusion be commenced as soon as practicable after preparation of the admixture. Infusion should be completed within 24 hours of preparation and the residue discarded. 6.4 Special precautions for storage Powder freeze dried for solution for injection: Store below 25°C RECONSTITUTION Cytarabine 1g vial is to be used for preparation of a solution for single dose administration. Cytarabine sterile powder can be dissolved in water for injection, 0.9% sodium chloride or 5% glucose in water with or without preservative. The maximum concentration that can be obtained after reconstitution with Cytarabine is 100mg/ml. In order to have a solution of exact 100mg/ml the following volume should be added: ml to add cytarabine 9.4 ml 1g 6.5 Nature and contents of container Vial glass type I, box of 1 vial 6.6 Special precautions for disposal and other handling 2020-0061980 Page 9 of 10 IMPORTANT No ampoule file is needed to open the ampoules. The neck of the ampoule is prescored at the point of constriction. A coloured dot on the ampoule head helps to orientate the ampoule. Take the ampoule and face the coloured dot. The ampoule opens easily by placing the thumb on the coloured dot and gently pressing downwards. Cytarabine 1g vial is to be used for preparation of a solution for single dose administration
שימוש לפי פנקס קופ''ח כללית 1994
לא צוין
תאריך הכללה מקורי בסל
01/01/1995
הגבלות
תרופה מוגבלת לשימוש בבתי חולים או אשפוז יום
יצרן
ACTAVIS ITALY S.P.A.בעל רישום
PFIZER PFE PHARMACEUTICALS ISRAEL LTDרישום
057 70 27036 00
מחיר
0 ₪
מידע נוסף